Raymond James & Associates 89bio, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in 89bio, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 227,953 shares of ETNB stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
227,953
Previous 182,943
24.6%
Holding current value
$1.79 Million
Previous $1.47 Million
15.09%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ETNB
# of Institutions
158Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Janus Henderson Group PLC London, X015.2MShares$119 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$111 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$62.8 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$58 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$55.1 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $365M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...